Center for Scientific Review; Notice of Closed Meetings, 10130-10131 [2015-03778]
Download as PDF
<![CDATA[
10130
Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices
progressive multifocal
leukoencephalopathy (PML), and
trichodysplasia spinulosa (TS). The
methods could also be used to restore
polyomavirus-specific immunity in
immunocompromised individuals.
Potential Commercial Applications:
Immunotherapy for immunosuppressed
individuals with polyomavirusassociated pathologies.
Competitive Advantages: Methods
allow development of polyomavirus
antigen-specific T cells.
Development Stage:
• Early-stage
• In vitro data available
Inventors: John A. Barrett (NHLBI),
Dhanalakshmi Chinnasamy (NHLBI),
Pawel J. Muranski (NHLBI), Christopher
B. Buck (NCI)
Intellectual Property: HHS Reference
No. E–166–2014/0—US Application No.
62/075,726 filed November 5, 2014
Related Technologies:
• HHS Reference No. E–168–2011
• HHS Reference No. E–549–2013
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
od.nih.gov
Collaborative Research Opportunity:
The National Heart, Lung, and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize methods to generate T
cells responsive to multiple
polyomaviruses. For collaboration
opportunities, please contact Dr.
Vincent Kolesnitchenko at kolesniv@
nhlbi.nih.gov.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
89Zr-Oxine
Complex for In Vivo PET
Imaging of Labelled Cells and
Associated Methods
Description of Technology: This
technology relates to a Zirconium-89
(89Zr)-oxine complex for cell labeling,
tracking of labeled cells by whole-body
positron emission tomography/
computed tomography (PET/CT)
imaging, and associated methods. A
long half-life of 89Zr (78.4 hours), high
sensitivity of PET and absence of
background signal in the recipient
enable tracking cells over a week using
low levels of labeling radioactivity,
without causing cellular toxicity. The
89Zr-oxine complex is synthesized
quickly by mixing components at room
temperature and produces high yields.
Cell labeling is achieved by a short,
room temperature incubation. The 89Zroxine complex is capable of labeling a
wide range of cell types of therapeutic
or pathogenic relevance (natural,
disease, engineered cells), independent
of factors such as cell cycle or receptor
expression. The label is retained during
VerDate Sep<11>2014
18:05 Feb 24, 2015
Jkt 235001
cell division. 89Zr-oxine labeled cells
can also be easily cross labeled (for
example, optically or magnetically) for
multi-modality imaging and analysis.
Labeled cell migration and kinetics can
be analyzed and quantified in vivo over
a week, improving research strategies
and ability to develop and improve cell
therapies and diagnostics.
Potential Commercial Applications:
Cell therapies and diagnostics.
Competitive Advantages: Simple
preparation, broadly applicable cell
label, high resolution imaging and
monitoring over period of a week, low
toxicity, easily combined with labeling
technologies and cell therapies.
Development Stage: In vivo data
available (animal).
Inventors: Noriko Sato (NCI), Haitao
Wu (NHLBI), Gary L. Griffiths (NCI),
Peter L. Choyke (NCI)
Publications:
1. Sato N, et al. Generation and use of
long-lasting cell labeling agent for
positron emission tomography (PET)
imaging. J Nucl Med. May 2014; 55
(Supplement 1):273.
2. Sato N, et al. 89Zr-oxine complex
positron emission tomography (PET)
cell imaging for monitoring cell-based
therapies. Radiology, 2015, In press.
Intellectual Property: HHS Reference
No. E–080–2014/0—US Patent
Application No. 61/973,706 filed April
1, 2014
Licensing Contact: Edward (Tedd)
Fenn; 424–297–0336; Tedd.fenn@
nih.gov
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize cell labeling, cell
tracking, cell trafficking, cell-based
therapy, PET imaging. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at john.hewes@nih.gov or
240–276–5515.
Dated: February 18, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–03779 Filed 2–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Autoimmunity Transplantation
Intolerance.
Date: March 11, 2015.
Time: 3:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Betty Hayden, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4206,
MSC 7812, Bethesda, MD 20892, 301–435–
1223, haydenb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Drug Discovery and Mechanisms of
Antimicrobial Resistance.
Date: March 13, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Guangyong Ji, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3211,
MSC 7808, Bethesda, MD 20892, 301–435–
1146, jig@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Skeletal
Muscle related SBIR/STTR.
Date: March 17, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Richard Ingraham, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4116,
MSC 7814, Bethesda, MD 20892, 301–496–
8551, ingrahamrh@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Project: Regulation of Cell Survival and
Death Pathways by Fe-S Proteins.
Date: March 19–20, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
E:\FR\FM\25FEN1.SGM
25FEN1
Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices
Contact Person: William A. Greenberg,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4168,
MSC 7806, Bethesda, MD 20892, (301) 435–
1726, greenbergwa@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 19, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–03778 Filed 2–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2013–1084]
Policy Letters: Guidance for the Use of
Liquefied Natural Gas as a Marine Fuel
Coast Guard, DHS.
Notice of availability.
AGENCY:
ACTION:
On February 7, 2014, the
Coast Guard announced the availability,
in the docket, of two draft policy letters
for which it sought public comment.
This notice announces the availability
of the finalized Coast Guard policy
letters, including explanations of
changes made to the policy letters and
enclosures based on the public
comments received. The first policy
letter provides voluntary guidance for
liquefied natural gas (LNG) fuel transfer
operations on vessels using natural gas
as fuel in U.S. waters, and training of
personnel on those vessels. It
recommends transfer and personnel
training measures that we believe will
achieve a level of safety that is at least
equivalent to that provided for
traditional fueled vessels. It applies to
vessels equipped to receive LNG for use
as fuel, but not to vessels regulated as
LNG carriers that utilize boil-off gas as
fuel. The second policy letter discusses
voluntary guidance and existing
regulations applicable to vessels and
waterfront facilities conducting LNG
marine fuel transfer (bunkering)
operations. The second policy letter
provides voluntary guidance on safety,
security, and risk assessment measures
we believe will enhance safe LNG
bunkering operations. Both policy
letters are available on the public
docket. They have been updated to
reflect publication numbers of the
current year. Accordingly, as discussed
asabaliauskas on DSK5VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:05 Feb 24, 2015
Jkt 235001
in this notice, Policy Letter 01–14
became Policy Letter 01–15 and Policy
Letter 02–14 became Policy Letter 02–
15.
FOR FURTHER INFORMATION CONTACT: If
you have questions on this notice, call
or email Ken Smith, Vessel and Facility
Operating Standards Division (CG–
OES–2), U.S. Coast Guard; telephone
202–372–1413, email Ken.A.Smith@
uscg.mil. If you have questions on
viewing or submitting material to the
docket, call Cheryl Collins, Program
Manager, Docket Operations, telephone
202–366–9826.
SUPPLEMENTARY INFORMATION:
Viewing material in the docket: To
view the policy letters and related
material, go to https://
www.regulations.gov, type the docket
number (USCG–2013–1084) in the
‘‘SEARCH’’ box and click ‘‘SEARCH.’’
Click on ‘‘Open Docket Folder’’ on the
line associated with this notice. If you
do not have access to the Internet, you
may view the docket online by visiting
the Docket Management facility in
Room W12–140 on the ground floor of
the Department of Transportation West
Building, 1200 New Jersey Avenue SE.,
Washington, DC 20590, between 9 a.m.
and 5 p.m., Monday through Friday,
except Federal holidays. We have an
agreement with the Department of
Transportation to use the Docket
Management Facility.
Privacy Act: Anyone can search the
electronic form of comments received
into any of our dockets by the name of
the individual submitting the comment
(or signing the comment, if submitted
on behalf of an association, business,
labor union, etc.). You may review a
Privacy Act, system of records notice
regarding our public dockets in the
January 17, 2008, issue of the Federal
Register (73 FR 3316).
Background and Purpose
The shipping industry is exploring
conversion from oil-based fuel to
cleaner burning natural gas, because the
use of natural gas as fuel would
substantially reduce carbon emissions,
sulfur emissions, and nitrogen oxide
emissions. This natural gas fuel would
be stored on and transferred to vessels
in the form of liquefied natural gas
(LNG). Existing regulations cover
design, equipment, operations, and
training of personnel on vessels that
carry LNG as cargo and at waterfront
facilities that handle LNG in bulk. They
also cover conventional oil fuel transfer
operations, but do not address LNG
transferred as fuel.1
1 33 CFR parts 127, 155 and 156; 46 CFR parts 10–
15, 30–39, and 154.
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
10131
On February 7, 2014, the Coast Guard
published two draft policy letters (CG–
OES 01–14 and CG–OES 02–14),
requesting comments, that
recommended the transfer procedures
and other operating guidelines for
vessels and waterfront facilities
providing LNG to vessels for use as fuel
and for vessels operating in U.S. waters
that will be fueled with natural gas that
will be stored onboard as LNG. The
Coast Guard has revised these policy
letters based on comments received and
now makes the final policy letters
available to the public.
The policy letters and voluntary
guidance do not apply to vessels
regulated as LNG carriers that utilize
their boil-off gas as fuel. They also do
not provide guidance on vessel design
criteria for natural gas fuel systems or
design of vessels providing LNG for use
as fuel. If you have questions about the
design of these systems, please contact
the Coast Guard’s Office of Design and
Engineering Standards (CG–ENG,
formerly CG–521). See FOR FURTHER
INFORMATION CONTACT section for contact
information.
Discussion
The Coast Guard received 27 letters
from the public containing a combined
total of 185 individual comments which
are discussed below. We discuss more
fully the changes we made to the policy
letters in response to comments.
All letters received were generally
supportive of the Coast Guard’s effort to
provide guidance on the use and
transfer of LNG as a marine fuel and the
Coast Guard appreciates this important
feedback.
We also received various comments
recommending changes that cannot be
made in a policy document because the
Coast Guard would need to undergo
rulemaking to make these recommended
changes enforceable. For example, one
submitter suggested that we provide
specific details concerning the
information that risk assessments
should contain. Another submitter
suggested that we provide common
checklists for industry to follow when
conducting bunkering operations. The
Coast Guard will consider these
comments and determine whether any
further action is necessary.
Additionally, the Coast Guard received
comments on matters unrelated to the
two policy letters discussed in this
notice. Those comments have been
reviewed but did not effect any changes
to these policy letters. Examples of some
of the comments we received pertaining
to design were related to venting
arrangements, LNG tank design, and gas
detection.
E:\FR\FM\25FEN1.SGM
25FEN1
]]>Agencies
[Federal Register Volume 80, Number 37 (Wednesday, February 25, 2015)]
[Notices]
[Pages 10130-10131]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-03778]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Autoimmunity Transplantation Intolerance.
Date: March 11, 2015.
Time: 3:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Betty Hayden, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4206, MSC 7812, Bethesda, MD 20892, 301-435-
1223, haydenb@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Drug Discovery and Mechanisms of Antimicrobial
Resistance.
Date: March 13, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: Guangyong Ji, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301-435-
1146, jig@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Skeletal Muscle related SBIR/STTR.
Date: March 17, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Richard Ingraham, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4116, MSC 7814, Bethesda, MD
20892, 301-496-8551, ingrahamrh@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Program Project: Regulation of Cell Survival and Death
Pathways by Fe-S Proteins.
Date: March 19-20, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
[[Page 10131]]
Contact Person: William A. Greenberg, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4168, MSC 7806, Bethesda, MD
20892, (301) 435-1726, greenbergwa@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: February 19, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-03778 Filed 2-24-15; 8:45 am]
BILLING CODE 4140-01-P
